Comparison of the effect of pegfilgrastim with filgrastim on the neutrophil count of cancer patients under chemotherapy.

Phase 3

• Conditions: Chemotherapy.; Encounter for antineoplastic chemotherapy and immunotherapy; Z51.1

• Registration Number: IRCT20180119038433N3
• Lead Sponsor: Semnan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 October 2020

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Having satisfaction
Age over 18 years
Chemotherapy in Omid ward of Kowsar hospital
History of at least 1 course of chemotherapy
Use myelosuppression chemotherapy drugs
Lack of allergy to pegfilrastim and filgrastim
Absence of underlying diseases

Exclusion Criteria

Patients with underlying disease
Allergy to pegfilgrastim or filgrastim
Severe fever and neutropenia in previous courses of chemotherapy
Patients with advanced cancer
Not consent to participate in the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
eutrophil count. Timepoint: Before the intervention and before the next round of chemotherapy. Method of measurement: Complete Blood cell count and Diffrential count.